Medication info
Sitagliptin and Metformin Extended-Release Tablets 50/500 mg

Sitagliptin and Metformin Extended-Release Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
GL Pharma Co., Ltd.
Appearance
Light blue, oval-shaped, biconvex, extended-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201876 · Approved 2022.05.09 · Insurance code 653806190

Summary

Main use
Improves blood glucose control in type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. This medicine 100/1000 mg extended-release tablets should be taken as 1 tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug treatment and inadequate glycemic control with monotherapy, or patients inadequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If this initial dose does not provide adequate glycemic control, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients inadequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients inadequately controlled with combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
GL Pharma Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes through the combination of sitagliptin and metformin. It is effective when used alongside dietary and exercise therapy, contributing to the stable management of blood sugar levels and the prevention of complications. Therefore, it is used for the treatment of patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. This medicine 100/1000 mg extended-release tablets should be taken as 1 tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug treatment and inadequate glycemic control with monotherapy, or patients inadequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If this initial dose does not provide adequate glycemic control, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients inadequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients inadequately controlled with combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication is composed of two active ingredients, sitagliptin and metformin, and is primarily used to assist in blood sugar control in patients with type 2 diabetes. First, sitagliptin may rarely cause severe allergic reactions; therefore, if symptoms like rash, hives, or difficulty breathing occur, the medication should be discontinued immediately and a doctor consulted. Additionally, serious side effects such as acute pancreatitis, which is inflammation of the pancreas, have been reported, so if abdominal pain, vomiting, or severe abdominal discomfort occur, prompt medical attention should be sought. The metformin component can cause lactic acidosis, a rare but potentially fatal metabolic disorder, and should not be taken by patients with impaired renal function, severe infections, dehydration, or liver diseases. Excessive alcohol intake may increase the risk of lactic acidosis, so it should be avoided while taking this medication. This medication should not be used in patients with reduced renal function, acute heart failure, or acute myocardial infarction, nor in women who are pregnant or breastfeeding, or in patients under 18 years of age. Regular tests of renal function and blood tests should be conducted while using this medication, and vitamin B12 levels should also be monitored periodically. Additionally, there is a risk of hypoglycemia, so caution should be exercised with irregular meals or intense exercise, and the risk of hypoglycemia should be more closely monitored when taken with insulin or other blood glucose-lowering agents. Before and after surgery or the use of iodine contrast agents for examinations, this medication should be temporarily discontinued and resumed only after confirming normal kidney function. Finally, if severe joint pain or skin blisters occur during the use of this medication, the physician should be notified immediately, and discontinuation of the drug may be required.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 18 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesiculobullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a tightly sealed container to protect it from air and moisture, and should be stored at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Light blue, oval-shaped, biconvex, extended-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.